NCT03088254

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.

Conditions

• Dyslipidemia With Hypertension

Interventions

Type	Name	Description
DRUG	Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)	Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
DRUG	Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)	Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
DRUG	Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)	Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks

Timeline

• Start date: 2016-09-20
• Primary completion: 2017-07-31
• Completion: 2017-12-04
• First posted: 2017-03-23
• Last updated: 2018-07-06

Locations

12 sites across 1 country: South Korea